The power of analytics is enabling the pharmaceutical industry to improve insights on drug safety to strengthen patient care at large. But limited data exists on the effectiveness of these various methodologies. In addition, there is an opportunity to identify new data sources and / or novel methodologies which could drive further understanding of product profiles and support product development. This initiative aims to develop best practices and guidance around the application of interrogative methods towards various safety data sources.
- Earlier identification of potential safety issues to help minimize harm to patients
- Improved quality data analytics and verified methodologies could enable a more informed product development outcome
- Accelerated method development and sharing of best practices through collaboration and piloting
Please check back for more information on the initiative assets in Q4-2019.